Related Experiment Video

Updated: May 14, 2026

Three-Dimensional (3D) Tumor Spheroid Invasion Assay
12:19

Three-Dimensional (3D) Tumor Spheroid Invasion Assay

Published on: May 1, 2015

EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme

Bryan W Day1, Brett W Stringer, Fares Al-Ejeh

  • 1Brain Cancer Research Unit and Leukaemia Foundation Research Unit, Queensland Institute of Medical Research, Brisbane 4006, Australia. bryan.day@qimr.edu.au

Cancer Cell
|February 16, 2013
PubMed

Insights

Researchers identified EphA3 as a key target in glioblastoma (GBM). This receptor tyrosine kinase is overexpressed in aggressive GBM subtypes and drives tumor growth by maintaining cancer stem cells. Targeting EphA3 shows promise for halting GBM progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Glioblastoma (GBM) is an aggressive brain cancer with limited therapeutic options.
  • Identifying novel therapeutic targets is crucial for halting GBM progression.

Purpose of the Study:

  • To investigate the role of EphA3 receptor tyrosine kinase as a potential therapeutic target in glioblastoma.
  • To determine if EphA3 expression correlates with GBM aggressiveness and tumor-initiating cell populations.

Main Methods:

  • Analysis of EphA3 expression in GBM patient samples, particularly in mesenchymal subtypes.
  • Investigating EphA3's role in maintaining cancer stem cell phenotype and modulating signaling pathways.
  • Assessing the impact of EphA3 knockdown and antibody-mediated targeting on tumor growth and tumorigenicity.

Main Results:

  • EphA3 is frequently overexpressed in GBM, especially in the aggressive mesenchymal subtype.
  • EphA3 is highly expressed on glioma tumor-initiating cells and promotes a less differentiated state.
  • Reducing EphA3 levels or targeting EphA3-positive cells significantly decreased tumor growth and tumorigenic potential.

Conclusions:

  • EphA3 is a functional and targetable receptor in glioblastoma.
  • Targeting EphA3 represents a promising therapeutic strategy for aggressive GBM.
  • EphA3 plays a critical role in maintaining the stemness of glioblastoma tumor-initiating cells.

More Related Videos

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice08:11

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice

Published on: September 26, 2011

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...